Fundraising FoxNovo Holdings — 2024 Investments
10 investments dated 2024 · listed companies and verified rows first · show all
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsBlackstone Life SciencesEight Roads VenturesF-Prime CapitalNYBC Ventures
Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs.
BiotechDeep TechHealthtechMedical Devices
Ryan Cirz(Co-founder & CEO)inAndrew McCandlish(Co-founder & COO)inPeter Smith(Chief Scientific Officer)inDaniel Cloutier(VP, Development)in
Co-investorsTenmile
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Founder)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)
Co-investorsThe Vertical GroupNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersSectoral Asset ManagementSofinnova Ventures+1 more
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.
BiotechHealthtechCopenhagen, DK
Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in
Co-investorsBroadview VenturesSR One Capital ManagementVersant Ventures
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersWellington ManagementFrazier Healthcare PartnersHBM Healthcare Investments+2 more
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.
BiotechDeep TechMedical DevicesCopenhagen, DK
Simon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)
Co-investorsInkefGilde HealthcareMC Healthcare Ventures
HepaRegeniX is a clinical-stage biotech company developing therapies that treat acute and chronic liver diseases by promoting liver regeneration.
BiotechHealthtechTuebingen, DE
Co-investorsBoehringer Ingelheim Venture FundHTGF
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
BiotechDeep TechHealthtechMedical Devices
Mohit Trikha(CEO)inSophia Randolph(Chief Medical Officer)in
Co-investorsBioGeneration VenturesBOMGimvHealthCapM VenturesRed Tree Venture
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsSanofi VenturesAlexandriaB CapitalDigitalis VenturesGlobal BioAccess FundLeaps by Bayer+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.